DA-EPOCH regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}DA-EPOCH; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen; EPOCH; EPOCH Regimen; EPOCH regim..." |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a chemotherapy regimen consisting of Dose-adjusted [[etoposide]], [[prednisone]], [[vincristine|vincristine (Oncovin)]] ,[[Cyclophosphamide]] and [[doxorubicin (hydroxydaunorubicin hycrochloride)]], which may be used in combination with [[rituximab]] (R-EPOCH) for the treatment of various aggressive B cell and T cell [[non-Hodgkin lymphomas]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63779 }}</ref> | {{PAGENAME}} refers to a chemotherapy regimen consisting of Dose-adjusted [[etoposide]], [[prednisone]], [[vincristine|vincristine (Oncovin)]] ,[[Cyclophosphamide]] and [[doxorubicin (hydroxydaunorubicin hycrochloride)]], which may be used in combination with [[rituximab]] (R-EPOCH) for the treatment of various aggressive B cell and T cell [[non-Hodgkin lymphomas]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63779 }}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|E|Etoposide}} | |||
{{chemo|P|Prednisone}} | {{chemo|P|Prednisone}} | ||
{{chemo|O|vincristine (Oncovin)}} | {{chemo|O|vincristine (Oncovin)}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
Revision as of 15:54, 12 March 2015
|
WikiDoc Resources for DA-EPOCH regimen |
|
Articles |
|---|
|
Most recent articles on DA-EPOCH regimen Most cited articles on DA-EPOCH regimen |
|
Media |
|
Powerpoint slides on DA-EPOCH regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on DA-EPOCH regimen at Clinical Trials.gov Trial results on DA-EPOCH regimen Clinical Trials on DA-EPOCH regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on DA-EPOCH regimen NICE Guidance on DA-EPOCH regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on DA-EPOCH regimen Discussion groups on DA-EPOCH regimen Patient Handouts on DA-EPOCH regimen Directions to Hospitals Treating DA-EPOCH regimen Risk calculators and risk factors for DA-EPOCH regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for DA-EPOCH regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:DA-EPOCH; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen; EPOCH; EPOCH Regimen; EPOCH regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin Regimen
Overview
DA-EPOCH regimen refers to a chemotherapy regimen consisting of Dose-adjusted etoposide, prednisone, vincristine (Oncovin) ,Cyclophosphamide and doxorubicin (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.[1]
Regimen
EEtoposide
PPrednisone
Ovincristine (Oncovin)
CCyclophosphamide
Hdoxorubicin (hydroxydaunorubicin hycrochloride)
Indications
References
- ↑ "NCI Thesaurus".
- ↑ Higashide Y, Hayashi T, Hirayama D, Wagatsuma K, Aoki Y, Maruyama Y; et al. (2015). "[A Case of Primary Mediastinal(Thymic)B-Cell Lymphoma Successfully Treated with the DA-EPOCH-RR egimen]". Gan To Kagaku Ryoho. 42 (1): 119–22. PMID 25596693.